PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
about
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesNintedanib in NSCLC: evidence to date and place in therapyRole of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?The possibility of traditional chinese medicine as maintenance therapy for advanced nonsmall cell lung cancerMaintaining clarity: Review of maintenance therapy in non-small cell lung cancerUpdate in Lung Cancer 2014Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidencePemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Emerging technologies for studying DNA methylation for the molecular diagnosis of cancerNew strategies in lung cancer: epigenetic therapy for non-small cell lung cancerCrizotinib-Induced Abnormal Signal Processing in the RetinaComplex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancerImproved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateeCROPS-CA: a systematic approach toward effective and sustainable cancer prevention in rural China.Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance statusPRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-sPhase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung CancerEffect of renal function on pemetrexed-induced haematotoxicitySafety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study.Long term responders to palliative chemotherapy for advanced biliary tract cancer.Treatment of advanced Gall bladder cancer in the real world-can continuation chemotherapy improve outcomes?Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidencePARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerAssociation between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancerRechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Tumor acquisition for biomarker research in lung cancerThe epidermal growth factor receptor (EGRF) in lung cancer.Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung CancerPemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT.Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancerThe role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.
P2860
Q26745422-02B81F29-FB3C-4720-A0E8-706E7BCE8164Q26745424-888A411F-4098-4CB1-832B-8FD77B1DDD00Q26767275-1DE8D6E5-CBF4-4804-A1AE-3492AE07CB47Q26798882-8584EA21-788E-4623-BF1D-AD68A64474EBQ26851282-75F0D27C-C857-4CFE-BF82-2682C8AC7EFEQ26996389-CCE27020-0A21-4A5D-A228-A71553AAA28DQ27027385-57F22586-4EEC-40B8-B4D4-A5D78545B27CQ28071772-83D3A1D9-B60E-437F-94BF-3816B642C94DQ28081243-8BF4A71C-E2B5-4390-B258-3397E54A0517Q28087759-B68835F0-FE32-48DB-9B01-2DD214ADF758Q28236190-55C1E4EE-C51C-4D97-91FC-3A86F3B8B71AQ28547218-5B00CEAF-9ADF-465A-8304-D1FDD830723CQ30300843-12A67EA7-C1A2-4B25-806B-486AE42A6B8FQ30316339-0B98A91F-F682-4FCA-90A9-09626FE662DDQ30356434-ED7CDAFA-335B-4041-9F9C-58FD060FBD10Q30646124-86DEE2A5-F080-4716-99E8-EC6A5D5091CEQ30784508-DA2B2624-E639-4790-8EFE-5AF4D1EB8D3CQ33414360-3D62BC34-CE9F-40C6-895B-5319383A2B22Q33417324-5BF72CBB-5E12-4521-A8B0-8B08FF178280Q33418542-4FCDF0DE-4202-4639-8B85-35F994E0D6BCQ33418595-10E22D08-CDBE-4220-87F9-FE570BB51AE4Q33420821-17114006-91C8-4C5F-A283-8562F4B5F2BEQ33429242-0C9ACD8F-F37B-4AA9-8544-D457EC725F7BQ33432955-F5A74867-614A-45A1-9650-DED4DB52463FQ33439970-78FEF483-C63D-4578-A8F1-867347E37681Q33593193-687C4CD7-304C-4572-BC84-6FC51BAA0DE7Q33593225-A69B9C9C-FCCA-40B9-967F-85453E0283F6Q34011705-F9BFC08E-BAFF-4D5C-AA36-A0FC10309247Q34041708-D426DD97-2BA8-4A7C-9728-21C8178DCFB4Q34245704-4A114A73-6946-42F8-80DB-3943A3D97A4EQ34259692-6691D982-6E02-4454-8553-A998AE9DD474Q34265773-076E38B7-EF52-4533-8618-7E6A57850B6AQ34490460-F296BBD9-1C3D-4913-A768-63AD6A302C4BQ34663877-773B7BE7-AC15-4785-941C-B707FBE61557Q35106814-5671C601-4260-47D1-BBA5-0DC22E2C22C2Q35196749-F2E64C94-56FF-4C8D-BB4D-4B4F18832841Q35812568-C585F19A-47DA-4D6A-AF59-C5940CC6D6B8Q35862294-F53BF76A-48C1-4A65-B1A3-2056FF09FF49Q35870217-02EB2564-0FDA-4C5E-882A-A9186F6C97BBQ36142491-4B5C48DC-C68B-498C-BD23-6FB4B8E7C2FB
P2860
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
PARAMOUNT: Final overall survi ...... us non-small-cell lung cancer.
@en
PARAMOUNT: Final overall survi ...... us non-small-cell lung cancer.
@nl
type
label
PARAMOUNT: Final overall survi ...... us non-small-cell lung cancer.
@en
PARAMOUNT: Final overall survi ...... us non-small-cell lung cancer.
@nl
prefLabel
PARAMOUNT: Final overall survi ...... us non-small-cell lung cancer.
@en
PARAMOUNT: Final overall survi ...... us non-small-cell lung cancer.
@nl
P2093
P356
P1476
PARAMOUNT: Final overall survi ...... us non-small-cell lung cancer.
@en
P2093
Annamaria H Zimmermann
Carla Visseren-Grul
Eckart Laack
Filippo de Marinis
Jean-Louis Pujol
Jesús Corral
Luis G Paz-Ares
Martin Reck
Michael Thomas
Mircea Dediu
P304
P356
10.1200/JCO.2012.47.1102
P407
P577
2013-07-08T00:00:00Z